Melissa L. Acreman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Melissa L. Acreman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Fabricio da Silva Costa
Maternal Fetal Medicine Unit, Gold Coast University Hospital and School of Medicine and Dentistry Griffith University Gold Coast QLD Australia
2 shared publications - Ben Willem Mol
Department of Obstetrics and Gynaecology Monash University Clayton Victoria Australia
1 shared publication Daniel L. Rolnik
Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia
1 shared publication- Daniel Lorber Rolnik
Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia
1 shared publication - Emily Schmidt
Development Strategy and Governance Division of the International Food Policy Research Institute (IFPRI), Washington, USA
1 shared publication Ilaria Fantasia
Obstetrics and Gynaecology Unit, San Salvatore Hospital, L'Aquila, Italy
1 shared publication
Latest Publications
- Open Access
- 8 February 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (6) , 549-559
The accuracy of cell‐free DNA screening for fetal segmental copy number variants: A systematic review and meta‐analysis
Background: The performance of cell‐free DNA (cfDNA) screening for microscopic copy number variants (CNVs) is unclear.Objectives: This was a systematic review and meta‐analysis to investigate the sensitivity, specificity and positive predictive value (PPV) of cfDNA screening for CNVs.Search Strategy: Articles published in EMBASE, PubMed or Web of Science before November 2022 were screened for inclusion. This protocol was registered with PROSPERO (23 March 2021, CRD42021250849) prior to initiation.Selection Criteria: Articles published in English, detailing diagnostic outcomes for at least 10 high‐risk CNV results with cfDNA were considered for inclusion.Data Collection and Analysis: The PPV was calculated and pooled with random‐effects models for double‐arcsine transformed proportions, using cases with diagnostic confirmation. Overall sensitivity, specificity and a summary receiver‐operating characteristics (ROC) curve were calculated using bivariate models. The risk of bias was assessed using QUADAS‐2.Main Results: In all, 63 articles were included in the final analysis, detailing 1 591 459 cfDNA results. The pooled PPV was 37.5% (95% confidence interval [CI] 30.6–44.8), with substantial statistical heterogeneity (I2 = 93.9%). Bivariate meta‐analysis estimated sensitivity and specificity to be 77.4% (95% CI 65.7–86.0) and 99.4% (95% CI 98.0–99.8), respectively, with an area under the summary ROC curve of 0.947 (95% CI 0.776–0.984).Conclusions: Approximately one‐third of women who screen high‐risk for CNVs with cfDNA will have an affected fetus. This value is of importance for screening counselling.
- 8 February 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (6) , 549-559
Open AccessThe accuracy of cell‐free DNA screening for fetal segmental copy number variants: A systematic review and meta‐analysis
Background: The performance of cell‐free DNA (cfDNA) screening for microscopic copy number variants (CNVs) is unclear.Objectives: This was a systematic review and meta‐analysis to investigate the sensitivity, specificity and positive predictive value (PPV) of cfDNA screening for CNVs.Search Strategy: Articles published in EMBASE, PubMed or Web of Science before November 2022 were screened for inclusion. This protocol was registered with PROSPERO (23 March 2021, CRD42021250849) prior to initiation.Selection Criteria: Articles published in English, detailing diagnostic outcomes for at least 10 high‐risk CNV results with cfDNA were considered for inclusion.Data Collection and Analysis: The PPV was calculated and pooled with random‐effects models for double‐arcsine transformed proportions, using cases with diagnostic confirmation. Overall sensitivity, specificity and a summary receiver‐operating characteristics (ROC) curve were calculated using bivariate models. The risk of bias was assessed using QUADAS‐2.Main Results: In all, 63 articles were included in the final analysis, detailing 1 591 459 cfDNA results. The pooled PPV was 37.5% (95% confidence interval [CI] 30.6–44.8), with substantial statistical heterogeneity (I2 = 93.9%). Bivariate meta‐analysis estimated sensitivity and specificity to be 77.4% (95% CI 65.7–86.0) and 99.4% (95% CI 98.0–99.8), respectively, with an area under the summary ROC curve of 0.947 (95% CI 0.776–0.984).Conclusions: Approximately one‐third of women who screen high‐risk for CNVs with cfDNA will have an affected fetus. This value is of importance for screening counselling.
- 23 August 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 228 (3) , 292-305.e6
The predictive value of prenatal cell-free DNA testing for rare autosomal trisomies: a systematic review and meta-analysis
- 23 August 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 228 (3) , 292-305.e6
The predictive value of prenatal cell-free DNA testing for rare autosomal trisomies: a systematic review and meta-analysis